-+ 0.00%
-+ 0.00%
-+ 0.00%

Bayer says China accepts aflibercept 8 mg filing for retinal vein occlusion macular edema review

PUBT·08/13/2026 06:36:13
Listen to the news
Bayer says China accepts aflibercept 8 mg filing for retinal vein occlusion macular edema review
  • Bayer’s application for aflibercept 8 mg to treat macular edema following retinal vein occlusion was accepted for regulatory review in China.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bayer AG published the original content used to generate this news brief on August 13, 2026, and is solely responsible for the information contained therein.